New medications for treatment of obesity: metabolic and cardiovascular effects.
Explore this paper's citation graph
Summary
Although hard clinical outcome benefit has yet to be established, obesity pharmacotherapy may soon address many of the challenges in the clinical management of obesity, although newer and better drug combinations and more evidence of benefit from appropriately designed outcome trials is needed.
- Type
- review
- Published
- 2015-02-01
- Cited by
- 50
- References
- 90
- OpenAlex
- https://openalex.org/W2099418146
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:35068482
Keywords
Medicine, Phentermine, Pharmacotherapy, Intensive care medicine, Bupropion
References
- Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
- Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials
- Impact of Weight-Loss Medications on the Cardiovascular System
- Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight‐loss outcomes
- Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- Incretin-based therapies for type 2 diabetes mellitus
- How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number.
- Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States
- Effects of Late Gestational High Fat Diet on Body Weight, Metabolic Regulation and Adipokine Expression in Offspring
- Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes
- Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity
- Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial
- Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- Topiramate: a new potential pharmacological treatment for obesity.
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an adjunct to Behavior Modification: The COR-BMOD Trial
- Vagal Nerve Dissection During Pouch Formation in Laparoscopic Roux-Y-Gastric Bypass for Technical Simplification: Does it Matter?
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity
Cited by
- Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity
- Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
- Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness.
- The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
- Naltrexone ER/Bupropion ER: A Review in Obesity Management
- Horizons in the Pharmacotherapy of Obesity
- CCR4-NOT2 Promotes the Differentiation and Lipogenesis of 3T3-L1 Adipocytes via Upregulation of PPARγ, CEBPα and Inhibition of P-GSK3α/β and β-Catenin
- European Guidelines for Obesity Management in Adults
- Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
- TGR5, cible thérapeutique pour le traitement du diabète de type 2 et ses complications métaboliques : de la chimie aux effets biologiques
- A Comparison of New Pharmacological Agents for the Treatment of Obesity
- Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
- Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches.
- Obesity: A Review of Pathogenesis and Management Strategies in Adult
- Human serum RNase-L level is inversely associated with metabolic syndrome and age
- Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation
- Definitions of obesity and current indications for obesity surgery
- Anti-obesity activity, acute toxicity, and chemical constituents of aqueous and ethanol Viola mandshurica extracts
- Cardiovascular disease prevention strategies for type 2 diabetes mellitus
- WEIGHT REDUCTION; TO EVALUATE IN OBESE PATIENTS WITH ORLISTAT AS COMPARED TO PLACEBO USING BODY MASS INDEX IN AN OPD SETTINGS
Related papers
- Obesity pharmacology: past, present, and future
- Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity
- Recent Advances in Anti-Obesity Agents
- [The pharmacological treatment of obesity: past, present and future].
- Current Concepts in the Pharmacological Management of Obesity
- Treatment of obesity: an update on anti‐obesity medications
- Long-Term Current Management of Enduring Obesity in Diabetes
- Weight-Loss Pharmacotherapy: A Brief Review
- Pharmacological treatment of obesity: present status